Solid-phase synthesis of thermolytic DNA oligonucleotides functionalized with a single 4-hydroxy-1-butyl or 4-phosphato-/thiophosphato-1-butyl thiophosphate protecting group

Journal of Organic Chemistry

Volumn 72, Issue 3, 2007, Pages 805-815

  Grajkowski, Andrzej ^a   Ausín, Cristina ^a   Kauffman, Jon S ^b   Snyder, John ^b   Hess, Sonja ^c   Lloyd, John R ^c   Beaucage, Serge L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Lancaster Laboratories   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDES; PHOSPHORAMIDITES; PHOSPHORYLATION; SOLID PHASE SYNTHESIS;

DISEASES; DRUG PRODUCTS; MATHEMATICAL MODELS; OLIGOMERS; SOLUBILITY; SYNTHESIS (CHEMICAL); WATER;

DNA;

CPG OLIGODEOXYNUCLEOTIDE; DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITE; OLIGONUCLEOTIDE; PHOSPHORAMIDOUS ACID DERIVATIVE; PHOSPHOROTHIOIC ACID DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; DIASTEREOISOMER; DRUG STRUCTURE; DRUG SYNTHESIS; IMMUNOTHERAPY; IN VITRO STUDY; PHOSPHORYLATION; SOLID;

ADJUVANTS, IMMUNOLOGIC; BASE SEQUENCE; DNA; MODELS, CHEMICAL; OLIGODEOXYRIBONUCLEOTIDES; ORGANOPHOSPHORUS COMPOUNDS; PRODRUGS; STEREOISOMERISM; THIONUCLEOTIDES; THIOPHOSPHORIC ACID ESTERS;

EID: 33846935981     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo062087y     Document Type: Article

References (54)

1. Iyer, R. P.; Yu, D.; Agrawal, S. Bioorg. Chem. 1995, 23, 1-21.
2. (a) Iyer, R. P.; Yu, D.; Agrawal, S. Bioorg. Med. Chem. Lett. 1994, 4, 2471-2476.
3. (b) Barber, I.; Rayner, B.; Imbach, J.-L. Bioorg. Med. Chem. Lett. 1995, 5, 563-568.
4. (c) Tosquellas, G.; Alvarez, K.; Dell'Aquilla, C.; Morvan, F.; Vasseur, J.-J.; Imbach, J.-L.; Rayner B. Nucleic Acids Res. 1998, 26, 2069-2074.
5. (d) Bologna, J.-C.; Morvan, F.; Imbach, J.-L. Eur. J. Org. Chem. 1999, 2353-2358.
6. (e) Morvan, F.; Brès, J.-C.; Lefebvre, I.; Vasseur, J.-J.; Pompon, A.; Imbach, J.-L. Nucleosides, Nucleotides & Nucleic Acids 2001, 20, 1159-1163.
7. (f) Morvan, F.; Bologna, J.-C.; Vivès, E.; Imbach, J.-L. Nucleosides, Nucleotides & Nucleic Acids 2001, 20, 1165-1168.
8. (g) Bologna, J.-C.; Vivès, E.; Imbach, J.-L.; Morvan, F. Antisense & Nucleic Acid Drug Dev. 2002, 12, 33-41.
9. (h) Iyer, R. P.; Yu, D.; Agrawal, S. Bioorg. Med. Chem. Lett. 1994, 4, 2471-2476.
10. (a) Iyer, R. P.; Yu, D.; Devlin, T.; Ho, N -H.; Agrawal, S. Bioorg. Med. Chem. Lett. 1996, 6, 1917-1922.
11. (b) Iyer, R. P.; Ho, N.-H.; Yu, D.; Agrawal, S. Bioorg. Med. Chem. Lett. 1997, 7, 871-876.
12. (a) Ora, M.; Mäki, E.; Poijärvi, P.; Neuvonen, K.; Oivanen, M.; Lönnberg, H. J. Chem. Soc., Perkin Trans. 2 2001, 881-885.
13. (b) Poijärvi, P.; Mäki, E.; Tomperi, J.; Ora, M.; Oivanen, M.; Lönnberg, H. Helv. Chim. Acta 2002, 85, 1869-1876.
14. (c) Poijärvi, P.; Oivanen, M.; Lönnberg, H. Lett. Org. Chem. 2004, 1, 183-188.
15. (d) Poijärvi, P.; Heinonen, P.; Virta, P.; Lönnberg, H. Bioconjugate Chem. 2005, 16, 1564-1571.
16. (a) Grajkowski, A.; Pedras-Vasconcelos, J.; Wang, V.; Ausín, C.; Hess, S.; Verthelyi, D.; Beaucage, S. L. Nucleic Acids Res. 2005, 33, 3550-3560.
17. (b) Grajkowski, A.; Pedras-Vasconcelos, J.; Ausín, C.; Verthelyi, D.; Beaucage, S. L. Ann. N.Y. Acad. Sci. 2005, 1058, 26-38.
18. PS(FMA) (ODN fma1556) results in complete suppression of the immunostimulatory properties of CpG ODN fma1555 in mice (see ref 5a).
19. The maximum concentration of CpG ODN fma1555 obtainable in water is ∼1 mM.
20. (a) Wilk, A.; Srinivasachar, K.; Beaucage, S. L. J. Org. Chem. 1997, 62, 6712-6713.
21. (b) Wilk, A.; Grajkowski, A.; Phillips, L. R.; Beaucage, S. L. J. Org. Chem. 1999, 64, 7515-7522.
22. (c) Wilk, A.; Grajkowski, A.; Srinivasachar, K.; Beaucage, S. L. Antisense & Nucleic Acid Drug Dev. 1999, 9, 361-366.
23. (d) Wilk, A.; Grajkowski, A.; Chmielewski, M. K.; Phillips, L. R.; Beaucage, S. L. In Current Protocols in Nucleic Acid Chemistry; Beaucage, S. L., Bergstrom, D. E., Glick, G. D., Jones, R. A., Eds.; John Wiley & Sons: New York, 2001; Vol. I, pp 2.7.1-2.7.12.
24. (a) Wilk, A.; Grajkowski, A.; Phillips, L. R.; Beaucage, S. L. J. Am. Chem. Soc. 2000, 122, 2149-2156.
25. (b) Grajkowski, A.; Wilk, A.; Chmielewski, M. K.; Phillips, L. R.; Beaucage, S. L. Org. Lett. 2001, 3, 1287-1290.
26. (c) Wilk, A.; Chmielewski, M. K.; Grajkowski, A.; Phillips, L. R.; Beaucage, S. L. Tetrahedron Lett. 2001, 42, 5635-5639.
27. (d) Wilk, A.; Chmielewski, M. K.; Grajkowski, A.; Phillips, L. R.; Beaucage, S. L. J. Org. Chem. 2002, 67, 6430-6438.
28. (e) Wilk, A.; Chmielewski, M. K.; Grajkowski, A.; Phillips, L. R.; Beaucage, S. L. In Current Protocols in Nucleic Acid Chemistry; Beaucage, S. L., Bergstrom, D. E., Glick, G. D., Jones, R. A., Eds.; John Wiley & Sons: New York, 2002; Vol. I, pp 3.9.1-3.9.16.
29. (f) Cieślak, J.; Beaucage, S. L. J. Org. Chem. 2003, 68, 10123-10129.
30. (g) Cieślak, J.; Grajkowski, A.; Livengood, V.; Beaucage, S. L. J. Org. Chem. 2004, 69, 2509-2515.
31. Even though only 7a, 8a, and 8b are required for the present work, phosphoramidites 8c,d were also prepared and characterized for use in experiments that are beyond the scope of this report.
32. Ausín, C.; Grajkowski, A.; Cieślak, J.; Beaucage, S. L. Org. Lett. 2005, 7, 4201-4204.
33. 31P NMR spectra of 7a and 8a-d are presented in the SI.
34. (a) Beaucage, S. L.; Iyer, R. P.; Egan, W.; Regan, J. B. Ann. N.Y. Acad. Sci. 1990, 616, 483-485.
35. (b) Iyer, R. P.; Egan, W.; Regan, J. B.; Beaucage, S. L. J. Am. Chem. Soc. 1990, 112, 1253-1254.
36. (c) Iyer, R. P.; Phillips, L. R.; Egan, W.; Regan, J. B.; Beaucage, S. L. J. Org. Chem. 1990, 55, 4693-4699.
37. (d) Regan, J. B.; Phillips, L. R.; Beaucage, S. L. Org. Prep. Proced. Int. 1992, 24, 488-492.
38. Ogilvie, K. K.; Beaucage, S. L. Nucleic Acids Res. 1979, 7, 805-824.
39. PST are shown in Chart 1 of the SI.
40. (a) Iwai, S.; Ohtsuka, E. Tetrahedron Lett. 1988, 29, 5383-5386.
41. (b) Iwai, S.; Ohtsuka, E. Nucleic Acids Res. 1988, 16, 9443-9456.
42. (c) Ueno, Y.; Shibata, A.; Matsuda, A.; Kitade, Y. Bioconjugate Chem. 2003, 14, 684-689.
43. RP-HPLC chromatogram of the dinucleotide is shown in Chart 13A of the SI.
44. This statement is substantiated by the rapid and homologous conversion of dinucleotide 6a to the hydroxybutylated dinucleotide 4 upon reaction with human alkaline phosphatase at 37°C.
45. Kataoka, M.; Hattori, A.; Okino, S.; Hyodo, M.; Asano, M.; Kawai, R.; Hayakawa, Y. Org. Lett. 2001, 3, 815-818.
46. Stawinski, J.; Strömberg, R. In Current Protocols in Nucleic Acid Chemistry; Beaucage, S. L., Bergstrom, D. E., Glick, G. D., Jones, R. A., Eds.; John Wiley & Sons: New York, 2001; pp 2.6.1-2.6.15 and references therein.
47. Hata, T.; Sekine, M. J. Am. Chem. Soc. 1974, 96, 7363-7364.
48. Lartia, R.; Asseline, U. Tetrahedron Lett. 2004, 45, 5949-5952.
49. (a) Letsinger, R. L.; Lunsford, W. B. J. Am. Chem. Soc. 1976, 98, 3655-3661.
50. (b) Letsinger, R. L.; Finnan, J. L.; Heavner, G. A.; Lunsford, W. B. J. Am. Chem. Soc. 1975, 97, 3278-3279.
51. Only hydrazinolysis was effective in the cleavage of the levulinyl group within an acceptable period of time at ∼25°C.
52. Boal, J. H.; Wilk, A.; Harindranath, N.; Max, E. E.; Kempe, T.; Beaucage, S. L. Nucleic Acids Res. 1996, 24, 3115-3117.
53. Koga, M.; Moore, M. F.; Beaucage, S. L. J. Org. Chem. 1991, 56, 3757-3759.
54. To ensure optimal formation of 8d, the reaction time was extended to 16 h at ∼25°C.